Tafnext

Tenofovir alafenamide hemifumarate

Chronic HBV infection in adults w/ compensated liver disease.

25 mg once daily.

Should be taken with food.

Severe acute exacerbations of HBV after discontinuation of treatment. Not recommended for the treatment of HIV-1 infection due to the risk of development of HIV-1 resistance. Patients coinfected w/ HBV & HIV-1; HIV Ab testing to all HBV-infected patients before initiating therapy. Renal impairment, including acute renal failure, proximal renal tubulopathy, & Fanconi syndrome. Discontinue if significant decreases in renal function or evidence of Fanconi syndrome develops. Suspend treatment if patient develops clinical or lab findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly & steatosis even in the absence of marked transaminase elevations). Concomitant use w/ nephrotoxic agents including NSAIDS. Assess serum creatinine, estimated CrCl, urine glucose, & urine protein in all patients & serum P in patients w/ CKD. Not recommended in patients w/ decompensated (Child Pugh B or C) hepatic impairment or patients w/ ESRD who are not receiving chronic hemodialysis. Pregnancy & lactation. Childn <18 yr.

Headache, abdominal pain, cough, back pain, fatigue, nausea, arthralgia, diarrhea, dyspepsia.

Decreased absorption & plasma conc w/ drugs that induce P-gp activity. Increased absorption & plasma conc w/ drugs that inhibit P-gp & BCRP. May increase conc w/ acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (eg, gentamicin), & high-dose or multiple NSAIDs. Decreased effect on conc w/ carbamazepine, oxcarbazepine, phenobarb, phenytoin, rifabutin, rifampin, rifapentine, & St. John's wort.

Antivirals

J05AF13 - tenofovir alafenamide ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.

Rx